Integrating a Molecular Signature of Intrinsic Radiosensitivity into the Classification of Breast Cancer J. F. Torres-Roca, W. J. Fulp, A. O. Naghavi,

Slides:

Advertisements

Similar presentations

Serena T. Wong, MD Assistant Professor of Medicine

Advertisements

Oncotype DX® Breast Cancer Assay Clinical Data Review

Molecular Systems Biology 3; Article number 140; doi: /msb

Implicaciones clínicas de los subtipos intrínsecos de cáncer de mama

Triple-Negative Breast Cancer

Is mammacarcinoom onder de veertig jaar morfologisch en genetisch een andere ziekte? Marc van de Vijver, Netherlands Cancer Institute, Amsterdam, NL.

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

Laura J. Van ‘t Veer Helen Diller Family Comprehensive Cancer Center University of California, San Francisco Biology of disease Who is at risk for what.

Departments - Surgery - Gerontology and Geriatrics Department of SurgeryDepartment of Gerontology & Geriatrics Prof. dr. C.J.H. van de VeldeProf. dr. R.G.J.

MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.

Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.

Model and Variable Selections for Personalized Medicine Lu Tian (Northwestern University) Hajime Uno (Kitasato University) Tianxi Cai, Els Goetghebeur,

Journal Club Cremona 24 Maggio 2008

MammaPrint, the story of the 70-gene profile

Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology.

2nd Quebec Conference on Therapeutic Resistance in Cancer Bienvenue !!!!!

The 70 gene Mammaprint ™ signature: a comparison with traditional clinico-pathological parameters. Patrizia Querzoli 1, Massimo Pedriali 1, Gardenia Munerato.

Exagen Diagnostics, Inc., all rights reserved Biomarker Discovery in Genomic Data with Partial Clinical Annotation Cole Harris, Noushin Ghaffari.

High-density lipoprotein and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory.

Dubsky P et al. Proc SABCS 2012;Abstract S4-3.

M. Kotlyar, C. A. Cumbaa, I. Jurisica Ontario Cancer Institute, Toronto, ON Posters 35 & 10.

Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,

Prognostic value of ER, PR, and HER2 breast cancer biomarkers and AJCC’s TNM staging system on overall survival of Caucasian females with breast cancer.

SP Cancer Metastasis Summary Hypothesis: We hypothesize that miRNAs regulate breast cancer cell invasiveness and metastasis by synergistically targeting.

Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.

Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.

Electromagnetic redesign of the HYPERcollar applicator: towards improved deep local head-and-neck hyperthermia *P. Togni, Z. Rijnen, W.C.M. Numan, R.F.

Effect of 21-Gene Reverse- Transcriptase Polymerase Chain Reaction Assay on Treatment Recommendations in Patients with Lymph Node-Positive and Estrogen.

Breast cancer 5 year survival rates (UK, 1975) by stage at diagnosis.

Jin MENG Shen FU (DPD 08) Biology 2 - Head/Neck and CNS Tumors

Scott Kopetz, MD, PhD Department of Gastrointestinal Medical Oncology

A B C Supplementary Figure S1. Time-dependent assessment of grade, GGI and PAM50 in untreated patients Landmark analyses of the Kaplan-Meier estimates.

Discussant Slides: Title: Radiosensitivity Index Shows Promise for Predicting Outcomes with Adjuvant Radiation in Resected Pancreatic Cancer Patients Poster.

Molecular subclasses of breast cancer: how do we deﬁne them? The IMPAKT 2012 Working Group Statement R4 신재령 / Prof. 김시영 Annals of Oncology 23: 2997–3006,

Chips? SNPs? or PCR? What do we really want and what do we need? Heinz-Josef Lenz, MD Professor of Medicine Co-Director, Colorectal Center Co-Director,

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer by Yun ‐ Yong Park, Kyounghyun Kim,

G Mustacchi 1, F Zanconati 2, D Bonifacio 2, L Morandi 3, MP Sormani 4, A. Gennari 5, P Bruzzi 4 1: Centro Oncolgico University of Trieste 2: Inst of Pathology,

Case 6 A 49 year old female was found to have a 1.3 cm spiculated mass on screening mammogram Ultrasound revealed a 1.2 cm hypoechoic mass with posterior.

Table S1: The results of ER, PgR, and HER2 status in IHC testing and mRNA expression in the full Consortium population (N=389) HER2 statusER status PgR.

San Antonio Breast Cancer Symposium – December 6-10, 2016

Figure 1 The heterogenous landscape of triple-negative breast cancer

Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.

KnowEnG: A SCALABLE KNOWLEDGE ENGINE FOR LARGE SCALE GENOMIC DATA

Hallett, et al., - Supplementary Figure 1

سرطان الثدي Breast Cancer

Jesper B. Andersen, Snorri S. Thorgeirsson Gastroenterology

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar

Wenlian Qiao, Peter W. Zandstra Cell Stem Cell

Tumor intrinsic subtype is reflected in cancer-adjacent tissue.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Marker reproducibility and metastasis prediction performance.

Volume 155, Issue 6, Pages (December 2018)

Continuing Adjuvant Tamoxifen to 10 Years

Subnetworks enriched for the hallmarks of cancer.

ADAM8 is overexpressed in human breast cancer AADAM8 mRNA expression in samples from breast tumor and normal breast tissue was analyzed using the Oncomine.

LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.

18th Annual Perspectives in Breast Cancer

Frequent alterations identified and potential actionability.

Development of 28 public molecular laboratories in France for molecular testing. Development of 28 public molecular laboratories in France for molecular.

Pre- and post-vorinostat values of ER-related gene expression using the Oncotype DX 21-gene assay. Pre- and post-vorinostat values of ER-related gene expression.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

Tamoxifen-treated patients.

Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical.

Molecular signatures are independent of tumor stage and grade.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

Clustering analysis of DTC-associated genes.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Location of the ER mutations and frequencies per cohort.

A, Proportion for different in silico predictions at the RNA level.

Presentation transcript:

Integrating a Molecular Signature of Intrinsic Radiosensitivity into the Classification of Breast Cancer J. F. Torres-Roca, W. J. Fulp, A. O. Naghavi, N. Servant, M. Bollet, M. J. van de Vijver, E. E. Harris, S. A. Eschrich Moffitt Cancer Center and Research Institute, Tampa FL Institut Curie, Paris, France Netherlands Cancer Institute, Amsterdam, Netherlands East Carolina University, Greenville, NC

Regulatory Networks Scale Torres-Roca J, et al. (2005) Cancer Res 65: Eschrich SA et-al (2009) IJROBP 75: Eschrich S et al (2009) IJROBP;75: Eschrich SA eta al (2012) Clin Can Res 18: Torres-Roca JF (2012) Per Med 9: Identification of Ten Genes in the Molecular Signature Confidential

RSI Predicts Local Recurrence in ER- and Triple Negative Patients

MVA: RSI Predicts Local Recurrence in ER- Patients

MVA: Combined RSI/Molecular Subtype Predicts Local Recurrence

Intrinsic Radiosensitivity into the Classification of Breast Cancer Conclusions – RSI in combination with molecular phenotype identifies novel sub-populations with a high risk of local recurrence after BCT